VYVGART
VYVGART®
Vyvgart® (efgartigimod alfa-fcab) is a FDA-approved treatment that uses a fragment of an IgG antibody to treat adults with anti-AChR antibody positive generalized myasthenia gravis (gMG).
VYVGART® HYTRULO is a combination of efgartigimod alfa, a neonatal Fc receptor blocker, and hyaluronidase, an endoglycosidase, indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive. (1)
For more information, visit the patient website for this drug. Speak with your healthcare provider to learn if this drug is right for you.
